Болезнь Фабри: особенности заболевания у детей и подростков
жүктеу/скачать 103,53 Kb. Pdf көрінісі
|
фарби
| Eur. Heart J
. 2007; 28: 1228–1235. 30. Pitz S., Grube-Einwald K., Renieri G., Reinke J. Subclinical optic neuropathy in Fabry disease. Ophthalmic Genet. 2009; 30: 165–171. 31. Hoffmann B., Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. (Suppl.) . 2007; 96: 84–86. 32. Linthorst G. E., Vedder A. C., Aerts J. M., Hollak C. E. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin. Chim. Acta. 2005; 353: 201–203. Doi: 10.1016/j.cccn.2004.10.019. 33. Kleijer W. J., Hussaarts-Odijk L. M., Sachs E. S., Jahoda M. G., Niermeijer M. F. Prenatal diagnosis of Fabry's disease by direct analysis of chorionic villi. Prenat. Diagn . 1987; 7 (4): 283–287. 34. Hoffmann B., Schwarz M., Mehta A., Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin. Gastroenterol. Hepatol. 2007; 5: 1447–1453. Doi: 10.1016/j.cgh.2007.08.012. 35. Anastasakis A., Papatheodorou E., Steriotis A. K. Fabry disease and cardiovascular involvement. Curr. Pharm. Des . 2013; 19 (33): 5997–6008. 36. Deegan P. B., Baehner A. F., Barba Romero M. A., Hughes D. A., Kampmann C., Beck M. European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet . 2006; 43: 347–352. 37. Waldek S., Patel M. R., Banikazemi M., Lemay R., Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 2009; 11: 790–796. 38. Ramaswami U., Stull D. E., Parini R., Pintos-Morell G., Whybra C., Kalkum G., Rohrbach M., Raluy-Callado M., Beck M., Chen W. H., Wiklund I. FOS Investigators. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ). Health Qual. Life Outcomes. 2012; 10: 116. 39. Palla A., Hegemann S., Widmer U., Straumann D. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J. Neurol . 2007; 254: 1433–1442. 40. Thofehrn S., Netto C., Cecchin C., Burin M., Matte U., Brusto lin S., Nunes A. C., Coelho J., Tsao M., Jardim L., Giugliani R., Bar ros E. J. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replace ment therapy: a Brazilian experience. Ren. Fail. 2009; 31: 773–778. 41. Tondel C., Bostad L., Larsen K. K., Hirth A., Vikse B. E., Houge G., Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol. 2013; 24: 137–148. 42. Caballero L., Climent V., Hernandez-Romero D., Quintanilla M. A., de la Morena G., Marin F. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations. Curr. Med. Chem. 2010; 17: 1679–1689. 43. Rozenfeld P. A., Fritz M., Blanco P., Gonzalez P., Rinaldi G. J. Myocardial alterations in the murine model of Fabry disease can be reversed by enzyme replacement therapy. Can. J. Cardiol. 2011; 27: 339–345. 44. Hoffmann B., Schwarz M., Mehta A., Keshav S. Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin. Gastroenterol. Hepatol . 2007; 5: 1447–1453. 45. Eng C. M., Guffon N., Wilcox W. R., Germain D. P., Lee P., Wal- deck S., Caplan L., Linthorst G. E., Desnick R. J. Safety and efficacy of recombinant human -galactosidase A — replacement therapy in Fabry's disease. жүктеу/скачать 103,53 Kb. Достарыңызбен бөлісу:
|